Broadcast Date:
- Time:
Antibody-drug conjugates (ADCs) represent a promising new therapeutic modality, delivering targeted, potent therapies directly to cancerous cells and offering hope for millions of patients worldwide. However, ADC manufacturing remains a complex, multi-step process with inherent challenges. Both early- and late-stage manufacturers must navigate the intricacies of handling highly potent payloads, maintaining consistent drug-antibody ratios (DAR), minimizing operator exposure, and ensuring product efficacy and safety.
In this GEN webinar, our expert speakers Zoltán Gulyás and Nigel Herbert will explore how next-generation technologies can help ADC manufacturers overcome these hurdles. Through three real-world case studies, you’ll learn how these innovative technologies can help to:
- Accelerate processing time and minimize risk to product and operators during tangential flow filtration (TFF)
- Maintain product consistency and operator safety while minimizing extractables and leachables
- Drive process efficiency and reduce turnaround time with accurate, real-time DAR measurement
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
